

Serum Levels of Pentraxin3 and Interlukin36 α in Patients with Systemic Lupus and their Relation to Disease Activity

Sahar M Ismail¹, Marwa K Abd EL-Wahab², Maha S Mohamed³

Departments of ¹Internal Medicine, ²Clinical Pathology and Physical Medicine, Rheumatology & Rehabilitation, Faculty of Medicine (for girls), Al -Azhar University, Cairo, Egypt.

Pentraxin3 (PTX3) plays an important role in inflammation, immunity, and atherosclerosis. Serum PTX3 has drawn attention as a marker that respond to local inflammation. Interleukin 36 (IL-36) is a novel inflammatory member of the IL-1 cytokine family comprising three different isoforms IL36 α , IL-36 β and IL-36 γ . The objective of this work was to evaluate the levels of PTX3 and IL36 α and to determine their relationships to disease activity in patients with systemic lupus erythematosus (SLE). Forty patients with SLE diagnosed according to SLECCA/ACR2012 criteria were allocated to the study, along with 20, age and sex matched normal control subjects. SLE patients included 20 patients with active disease, each having SLEADI score over 6 points and the other 20 patients, each of them had SLEADI score less than 6 points. Levels of serum PTX3 and IL36 α was measured by quantitative sandwich enzyme immunoassay technique. There was a significant increase in the serum pentraxin3 and IL36 α in SLE patients ($P < 0.01$) compared to normal control subjects. The significance increased in serum levels of PTX3 and IL-36 α , was noted in active ($P = 0.000$ for both) and inactive SLE patients ($P = 0.003$ and $P = 0.001$, respectively), compared to normal control subjects. Moreover, the active SLE patients had significant increase in the serum levels of PTX3 and IL36 α ($P < 0.01$ for both) compared to the inactive group of patients. A significant positive correlation between each of PTX3 and IL36 α , and SLEADI score ($P = 0.008$ and $P = 0.024$, respectively) in SLE patients was observed. In conclusion, PTX3 and IL36 α serum levels are increased in SLE patients when compared to normal control subjects, correlated positively with SLEADI score and thus could be used as markers of disease activity.